Literature DB >> 11992250

Unusual splice-site mutations in the RSK2 gene and suggestion of genetic heterogeneity in Coffin-Lowry syndrome.

Maria Zeniou1, Solange Pannetier, Jean-Pierre Fryns, André Hanauer.   

Abstract

Coffin-Lowry syndrome (CLS) is a syndromic form of X-linked mental retardation that is characterized, in male patients, by psychomotor and growth retardation and various skeletal anomalies. Typical facial changes and specific clinical and radiological hand aspects exhibited by patients are essential clues for the diagnosis. CLS is caused by mutations in a gene that is located in Xp22.2 and that encodes RSK2, a growth-factor-regulated protein kinase. RSK2 mutations are extremely heterogeneous and lead to premature termination of translation and/or loss of phosphotransferase activity. Surprisingly, among a series of 250 patients screened by single-strand conformation polymorphism (SSCP) analysis, in whom a clinical diagnosis of CLS was made, no mutations were detected in 66% (165) of the patients. To determine what proportion of these latter patients have a RSK2 mutation that has not been detected and what proportion have different disorders that are phenotypically similar to CLS, we have, in the present article, investigated, by western blot analysis and in vitro kinase assay, cell lines from 26 patients in whom no mutation was previously identified by SSCP analysis. This approach allowed us to identify seven novel RSK2 mutations: two changes in the coding sequence of RSK2, one intragenic deletion, and four unusual intronic nucleotide substitutions that do not affect the consensus GT or AG splice sites. We have also determined the nucleotide sequence of the promoter region of the RSK2 gene, and we have screened it for mutations. No disease-causing nucleotide change was identified, suggesting that mutations affecting the promoter region are unlikely to account for a large number of patients with CLS. Finally, our results provide evidence that some patients have a disease that is phenotypically very similar to CLS, which is not caused by RSK2 defects. This suggests that there are defects in either additional genes or combinations of genes that may result in a CLS-like phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992250      PMCID: PMC379129          DOI: 10.1086/340607

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  24 in total

1.  Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms.

Authors:  M Orita; H Iwahana; H Kanazawa; K Hayashi; T Sekiya
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

2.  Coffin-Lowry syndrome: a multicenter study.

Authors:  S Gilgenkrantz; P Mujica; P Gruet; P Tridon; F Schweitzer; A Nivelon-Chevallier; J L Nivelon; G Couillault; A David; A Verloes
Journal:  Clin Genet       Date:  1988-10       Impact factor: 4.438

3.  Probable localisation of the Coffin-Lowry locus in Xp22.2-p22.1 by multipoint linkage analysis.

Authors:  A Hanauer; Y Alembik; S Gilgenkrantz; P Mujica; A Nivelon-Chevallier; M E Pembrey; I D Young; J L Mandel
Journal:  Am J Med Genet       Date:  1988 May-Jun

4.  The Coffin-Lowry syndrome. Experience from four centres.

Authors:  A G Hunter; M W Partington; J A Evans
Journal:  Clin Genet       Date:  1982-05       Impact factor: 4.438

5.  Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome.

Authors:  E Trivier; D De Cesare; S Jacquot; S Pannetier; E Zackai; I Young; J L Mandel; P Sassone-Corsi; A Hanauer
Journal:  Nature       Date:  1996-12-12       Impact factor: 49.962

6.  Coffin-Lowry syndrome: clinical aspects at different ages and symptoms in female carriers.

Authors:  A S Plomp; C E De Die-Smulders; P Meinecke; J M Ypma-Verhulst; D A Lissone; J P Fryns
Journal:  Genet Couns       Date:  1995

7.  Brief clinical report: early recognition of the Coffin-Lowry syndrome.

Authors:  W G Wilson; T E Kelly
Journal:  Am J Med Genet       Date:  1981

8.  Confirmation and refinement of the genetic localization of the Coffin-Lowry syndrome locus in Xp22.1-p22.2.

Authors:  V Biancalana; M L Briard; A David; S Gilgenkrantz; J Kaplan; M Mathieu; C Piussan; J Poncin; A Schinzel; C Oudet
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

9.  Cloning of a human insulin-stimulated protein kinase (ISPK-1) gene and analysis of coding regions and mRNA levels of the ISPK-1 and the protein phosphatase-1 genes in muscle from NIDDM patients.

Authors:  C Bjørbaek; T A Vik; S M Echwald; P Y Yang; H Vestergaard; J P Wang; G C Webb; K Richmond; T Hansen; R L Erikson
Journal:  Diabetes       Date:  1995-01       Impact factor: 9.461

10.  Construction of a high-resolution linkage map for Xp22.1-p22.2 and refinement of the genetic localization of the Coffin-Lowry syndrome gene.

Authors:  V Biancalana; E Trivier; C Weber; J Weissenbach; P S Rowe; J L O'Riordan; M W Partington; S Heyberger; C Oudet; A Hanauer
Journal:  Genomics       Date:  1994-08       Impact factor: 5.736

View more
  5 in total

1.  Treatment of drop episodes in Coffin-Lowry syndrome.

Authors:  Sean O'Riordan; M Patton; F Schon
Journal:  J Neurol       Date:  2005-07-20       Impact factor: 4.849

2.  Delineation of the mechanisms of aberrant splicing caused by two unusual intronic mutations in the RSK2 gene involved in Coffin-Lowry syndrome.

Authors:  Maria Zeniou; Renata Gattoni; André Hanauer; James Stévenin
Journal:  Nucleic Acids Res       Date:  2004-02-18       Impact factor: 16.971

Review 3.  Coffin-Lowry syndrome.

Authors:  Patricia Marques Pereira; Anne Schneider; Solange Pannetier; Delphine Heron; André Hanauer
Journal:  Eur J Hum Genet       Date:  2009-11-04       Impact factor: 4.246

Review 4.  Coffin-Lowry syndrome: clinical and molecular features.

Authors:  A Hanauer; I D Young
Journal:  J Med Genet       Date:  2002-10       Impact factor: 6.318

Review 5.  Perturbed proteostasis in autism spectrum disorders.

Authors:  Susana R Louros; Emily K Osterweil
Journal:  J Neurochem       Date:  2016-08-04       Impact factor: 5.372

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.